Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 5/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28335243 | 0.97 | CCR1 (0.50) | CCR1CCR8CYP2A6GRM5NOS3 | |
| Pyridine SCHEMBL4589889 | 0.89 | GRM5 (0.52) | CCR1CCR8CYP2A6GRM5NOS3 | |
| Pyridine SCHEMBL28172263 | 0.85 | GRM5 (0.41) | CCR1CCR8CYP2A6GRM5NOS3 | |
| Pyridine SCHEMBL28169149 | 0.84 | ALDH1A1 (0.47) | CYP2A6GRM5TSHRRAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL14965070 | 0.83 | CCR1 (0.63) | CCR1CCR8CYP2A6GRM5NOS3 | |
| SCHEMBL9611 | 0.83 | — | — | |
| SCHEMBL30421349 | 0.83 | — | — | |
| SCHEMBL1771685 | 0.83 | CCR1 (0.71) | CCR1CCR8CYP2A6GRM5NOS3 | |
| Hydrochloric Acid SCHEMBL15145084 | 0.80 | CCR1 (0.60) | CCR1CCR8CYP2A6GRM5NOS3 | |
| SCHEMBL184761 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973919-B1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | ABBOTT LAB (US) | 2014-09-03 | — | — | EP | claimed |
| CN-113874402-B | Polar group-containing olefin copolymer | 国立大学法人东京大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4058455-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-113874402-A | Polar group-containing olefin copolymer | 国立大学法人东京大学 | 2021-12-31 | — | — | CN | disclosed |
| US-11059854-B2 | Method for preparing steroid derivative FXR agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-07-13 | — | — | US | disclosed |
| WO-2021097116-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3790859-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3761985-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University - Of The Commonwealth System of Higher Education (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200231622-A1 | METHOD FOR PREPARING STEROID DERIVATIVE FXR AGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-23 | — | — | US | disclosed |
| WO-2019217890-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019173633-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-09-12 | — | — | WO | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-1718629-B1 | Benzopyran compounds useful for the treatment of arrhytmia | NISSAN CHEMICAL IND LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| CN-1191235-C | Process for preparing substd. pyridines compounds | PFIZER PROD INC (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| CN-1320596-A | Process for preparing substd. pyridines compounds | PFIZER PROD INC (US) | 2001-11-07 | — | — | CN | disclosed |
| US-4093522-A | WITH WATER SOLUBLE PYRIDINIUM, QUINOLINIUM OR ACRIDINIUM SULFATE AND HALIDE | DILLENBERG HORST | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059854-B2 | Method for preparing steroid derivative FXR agonist | FXR1, NR1H4, FXR2 | CCR1 1008/4885CCR8 704/4885CYP2A6 82/4885 |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | CCR1 316/4885CCR8 1599/4885CYP2A6 3568/4885 |
| US-20200231622-A1 | METHOD FOR PREPARING STEROID DERIVATIVE FXR AGONIST | FXR1, NR1H4, FXR2 | CCR1 1008/4885CCR8 704/4885CYP2A6 82/4885 |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | CCR1 1373/4885CCR8 628/4885CYP2A6 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.